A single center study assessing the onset and disease course of inflammatory Arthritis in patients receiving Immune Checkpoint Inhibitor therapy
Latest Information Update: 18 Jan 2021
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Bladder cancer; Malignant melanoma; Non-small cell lung cancer; Renal cancer
- Focus Adverse reactions
Most Recent Events
- 18 Jan 2021 New trial record